☢️ CPT 52250 — Cystourethroscopy With Insertion Of Radioactive Substance, With Or Without Biopsy Or Fulguration
Quick Reference
wRVU: 4.38 | Global Period: 000 | Assistant Payable: No | Bilateral Indicator: 0 Rule: CPT 52250 carries an assistant-at-surgery indicator of 1, meaning statutory restrictions apply and an assistant surgeon may not be separately paid. Co-surgery and team surgery are not permitted (indicator 0). Because the bladder is a single midline organ, bilateral modifiers do not apply, and the code shares an endoscopic base group with 52000, so multiple-endoscopy payment reduction rules apply when billed with other cystourethroscopy codes on the same date.
📋 Clinical Description
CPT 52250 describes a transurethral cystourethroscopic procedure in which the surgeon passes a cystoscope through the urethra into the bladder to place a radioactive substance — historically radioactive gold grains, radon seeds, or Iodine-125 implants — directly into or adjacent to a bladder tumor for localized radiotherapy. The code descriptor explicitly allows for incidental biopsy or fulguration during the same encounter without requiring separate reporting of those components, distinguishing it from 52204 (biopsy only) and 52224 (fulguration of a minor lesion).
This procedure is far less commonly performed today than in prior decades, since systemic and intravesical chemotherapy or immunotherapy (e.g., BCG) have largely supplanted interstitial radioactive seed placement for bladder malignancy; however, the code remains active and separately payable for the rare cases in which brachytherapy-style radioactive substance placement is clinically selected. Compared to 52240, which addresses fulguration or resection of a large bladder tumor without radioactive material, CPT 52250 is defined specifically by the radioactive-substance component, regardless of tumor size.
This procedure may be performed in the following clinical contexts:
- Localized bladder malignancy treatment — radioactive substance placement is used as an adjunct or alternative to systemic therapy for a discrete, endoscopically accessible tumor.
- Recurrent bladder cancer after prior resection — used when tumor recurs in a location amenable to direct radioactive implantation rather than repeat resection.
- Combined diagnostic and therapeutic session — a biopsy may be obtained from the same or an adjacent site immediately before radioactive substance placement to confirm histology.
- Palliative local control — used in select patients for whom systemic therapy is not tolerated and local tumor control is the treatment goal.
🔬 Anatomical & Procedural Considerations
| Variant | Mechanism | Key Notes |
|---|---|---|
| Radioactive substance insertion alone | The cystoscope is advanced through the urethra into the bladder under direct visualization; a delivery instrument places the radioactive source (seed, grain, or catheter-based isotope) directly into or immediately adjacent to the target lesion. | This is the base component of the code and is reportable even when no biopsy or fulguration is performed, since the descriptor uses “with or without.” |
| With biopsy | Prior to or immediately following radioactive substance placement, a biopsy forceps is passed through the cystoscope to obtain tissue from the tumor or surrounding mucosa for pathologic confirmation. | The biopsy is bundled into 52250 and is not separately reported with 52204 when performed at the same session on the same lesion. |
| With fulguration | An electrosurgical or laser probe is used to cauterize bleeding or residual tumor margins around the implantation site. | Fulguration performed as part of this session is bundled and should not be separately billed with 52214 or 52224. |
Clinical Pearl
Because CPT 52250 already incorporates biopsy and fulguration in its descriptor, auditors frequently flag claims that separately report 52204 or 52224 on the same date of service for the same bladder lesion. Confirm operative documentation specifies radioactive substance placement — without it, the correct code is 52204, 52224, or 52240 depending on the actual work performed.
✅ Procedure Includes
- Cystoscopic insertion and passage through the urethra into the bladder under direct endoscopic visualization.
- Placement of a radioactive substance into or adjacent to a bladder lesion for localized radiotherapy.
- Incidental biopsy of the treated lesion or surrounding tissue, if performed in the same session.
- Incidental fulguration of the treated site or a bleeding vessel, if performed in the same session.
- Irrigation of the bladder before and after the procedure.
- Post-procedure inspection of the bladder and urethra for hemostasis.
❌ Excludes / Do Not Report Together
| Code | Description | Relationship |
|---|---|---|
| 52204 | Cystourethroscopy with biopsy(s) | Bundled into 52250 when the biopsy is taken as part of the radioactive substance placement session; do not report separately for the same lesion on the same date. |
| 52224 | Cystourethroscopy with fulguration or treatment of a minor bladder lesion | Bundled into 52250 when fulguration is performed at the same operative site during radioactive substance insertion. |
| 52240 | Cystourethroscopy with fulguration and/or resection of a large bladder tumor | Represents an alternative treatment pathway without radioactive material; report only one of the two codes based on the actual modality used, not both. |
| 52000 | Cystourethroscopy, diagnostic (separate procedure) | Considered inherent to 52250 as the endoscopic access route; not separately reportable when 52250 is performed. |
Bundling Alert
CPT 52250 has a 000-day global period, so there is no post-operative period to protect against unrelated same-day billing, but same-session diagnostic cystoscopy, biopsy, and fulguration at the treated site are considered integral and bundled under NCCI edits. Because the assistant-at-surgery indicator is 1, claims with modifiers -80, -81, -82, or -AS will be denied absent documented statutory exception. Auditors also watch for inappropriate use of modifier -51 given the code’s shared endoscopic base group with other 52000-series codes, which already triggers automatic multiple-endoscopy payment reduction.
🌳 Code Tree — Surgery: Urinary System, Bladder
CPT 51500-52700 Surgery: Urinary System — Bladder
│
├── 51500-51999 Bladder Incision, Excision, Repair
│ ├── 51550 Partial removal of bladder
│ └── 51999 Unlisted laparoscopic procedure, bladder
│
├── 52000-52700 Transurethral Surgery (Cystourethroscopy)
│ ├── 52204 Cystourethroscopy with biopsy(s)
│ ├── 52235 Cystourethroscopy with fulguration and/or resection of medium bladder tumor(s) (2.0 to 5.0 cm)
│ ├── 52240 Cystourethroscopy with fulguration and/or resection of large bladder tumor(s)
│ ├── ▶▶ 52250 ◀◀ Cystourethroscopy with insertion of radioactive substance, with or without biopsy or fulguration ← YOU ARE HERE (Global: 000)
│ ├── 52260 Cystourethroscopy with dilation of bladder for interstitial cystitis; general or conduction anesthesia
│ └── 52265 Cystourethroscopy with dilation of bladder for interstitial cystitis; local anesthesia
│
└── 52276-52700 Cystourethroscopy — Urethral and Stone Procedures
├── 52282 Cystourethroscopy with insertion of permanent urethral stent
└── 52356 Cystourethroscopy with ureteroscopy and/or pyeloscopy with lithotripsy and stent insertion💰 RVU & Reimbursement Profile
| Component | Value |
|---|---|
| Work RVU | 4.38 |
| Global Period | 000 |
| Bilateral Indicator | 0 — bilateral adjustment does not apply |
| Assistant Surgeon | Statutory restriction — not payable (indicator 1) |
| Co‑Surgeon | Not permitted (indicator 0) |
| Team Surgery | Not permitted (indicator 0) |
| PC/TC Split | 0 — physician service code, no PC/TC split applies |
| Modifier -51 Exempt | No — subject to multiple-endoscopy reduction rules via base code 52000 |
| Anesthesia | Typically local, regional, or general depending on tolerance and extent of the procedure |
Bilateral Billing Rules
🏷️ Modifier Reference
| Modifier | Name | When to Apply |
|---|---|---|
| -22 | Increased Procedural Services | Apply when the radioactive substance placement is substantially more complex or time-consuming than typical, such as multiple implantation sites, with clear operative documentation of the extra work. |
| -25 | Significant, Separately Identifiable E/M | Apply when a significant, separately identifiable evaluation and management service is performed by the same physician on the same day as the procedure, unrelated to the decision to proceed with 52250. |
| -51 | Multiple Procedures | Apply when 52250 is reported with another significant, separately identifiable procedure performed at the same session, understanding that automatic multiple-endoscopy pricing rules already apply within the 52000 family. |
| -52 | Reduced Services | Apply when the radioactive substance placement is intentionally reduced or partially completed relative to the full procedure, such as when only a portion of the planned implantation is achieved. |
| -53 | Discontinued Procedure | Apply when the procedure is started but terminated due to extenuating circumstances or patient risk before radioactive substance placement is completed. |
| -58 | Staged or Related Procedure | Apply when a planned, staged, or more extensive related procedure is performed by the same physician during the post-operative period of a prior related surgery. |
| -59 | Distinct Procedural Service | Apply when 52250 is performed at a separate lesion, session, or anatomic site distinct from another same-day bladder procedure that would otherwise be bundled. |
| -76 | Repeat Procedure by Same Physician | Apply when the same physician repeats the identical radioactive substance placement procedure on the same day, such as a staged bilateral-site implantation in a single visit. |
| -77 | Repeat Procedure by Another Physician | Apply when a different physician repeats the identical procedure on the same day, such as a covering urologist completing a planned second-site implantation. |
| -78 | Unplanned Return to OR | Apply when the patient returns to the operating room during the post-operative period for a complication directly related to the initial radioactive substance placement. |
| -79 | Unrelated Procedure by Same Physician | Apply when the same physician performs an unrelated procedure during the post-operative period of a prior, unrelated surgery. |
🩺 Common ICD‑10‑CM Pairings
Primary Diagnosis Group
| ICD‑10 | Description | HCC? | Notes |
|---|---|---|---|
| C67.0 | Malignant neoplasm of trigone of bladder | Yes | Supports medical necessity when the tumor targeted for radioactive substance placement is located at the trigone. |
| C67.1 | Malignant neoplasm of dome of bladder | Yes | Use when the treated lesion is documented at the dome of the bladder. |
| C67.9 | Malignant neoplasm of bladder, unspecified | Yes | Use only when the operative or pathology report does not document a specific bladder subsite; more specific codes are preferred when available. |
| D09.0 | Carcinoma in situ of bladder | No | Appropriate when the treated lesion is confirmed as carcinoma in situ rather than invasive malignancy. |
| D41.4 | Neoplasm of uncertain behavior of bladder | No | Use when pathology has not yet determined malignant versus benign behavior at the time of the procedure. |
Secondary Group
| ICD‑10 | Description | HCC? | Notes |
|---|---|---|---|
| Z85.51 | Personal history of malignant neoplasm of bladder | No | Supports surveillance-related repeat procedures in patients previously treated for bladder cancer. |
| Z12.6 | Encounter for screening for malignant neoplasm of bladder | No | Rarely primary for this therapeutic code but may be listed as secondary when screening findings prompted the treatment encounter. |
Etiology / Complication
| ICD‑10 | Description | HCC? | Notes |
|---|---|---|---|
| R31.0 | Gross hematuria | No | Supports the diagnostic workup that preceded identification of the treated lesion. |
| R31.1 | Benign essential microscopic hematuria | No | Use only when microscopic hematuria specifically prompted the evaluation leading to the treated lesion; avoid pairing with a confirmed malignant primary unless both are separately documented. |
Coding Specificity Reminder
Always code to the highest specificity documented in the pathology and operative report. Use a site-specific bladder neoplasm code (trigone, dome, lateral wall, anterior wall, posterior wall, bladder neck, ureteric orifice, urachus, or overlapping sites) whenever the location is documented, and reserve C67.9 for cases where the record truly does not specify a subsite.
🏥 MS‑DRG Considerations
CPT 52250 is almost always performed in the outpatient or ASC setting given its 000-day global period, so it typically does not independently drive inpatient MS-DRG assignment; when performed during an inpatient admission, the corresponding ICD-10-PCS codes below are what group the encounter. There is no National Coverage Determination (NCD) specific to CPT 52250; coverage nationally is instead governed by Medicare Administrative Contractor Local Coverage Determinations (LCDs) for cystourethroscopy, which generally require medical necessity documentation and a qualifying diagnosis such as a bladder neoplasm code, gross or microscopic hematuria, or personal history of bladder malignancy. Commercial payers apply comparable utilization management criteria, illustrated by Anthem’s Clinical UM Guideline CG-SURG-51 (Outpatient Cystourethroscopy), which lists 52250 as medically necessary only when a qualifying indication such as documented bladder malignancy, hematuria, or suspected malignant involvement of the urinary tract is present and supported in the record.
🔧 ICD‑10‑PCS Equivalents
| PCS Code | Full Description | Modality |
|---|---|---|
| 0THB8MZ | Insertion of Radioactive Element into Bladder, Via Natural or Artificial Opening Endoscopic | Endoscopic brachytherapy-style implantation |
| 0TBB8ZX | Excision of Bladder, Via Natural or Artificial Opening Endoscopic, Diagnostic | Endoscopic biopsy |
| 0T5B8ZZ | Destruction of Bladder, Via Natural or Artificial Opening Endoscopic | Endoscopic fulguration |
| 0TJB8ZZ | Inspection of Bladder, Via Natural or Artificial Opening Endoscopic | Diagnostic cystoscopic visualization |
PCS Character Analysis (primary code 0THB8MZ)
| Position | Character | Value | Definition |
|---|---|---|---|
| 1 | Section | 0 | Medical and Surgical section, the root category for the radioactive substance placement procedure. |
| 2 | Body System | T | Urinary System, since the bladder is the target organ. |
| 3 | Root Operation | H | Insertion, defined as putting in a non-biological device that monitors, assists, performs, or prevents a physiological function without taking over that function. |
| 4 | Body Part | B | Bladder, the specific organ into which the radioactive element is placed. |
| 5 | Approach | 8 | Via Natural or Artificial Opening Endoscopic, reflecting the transurethral cystoscopic route. |
| 6 | Device | M | Radioactive Element, the device value assigned to implanted radioactive sources such as seeds or grains. |
| 7 | Qualifier | Z | No Qualifier, since no additional qualifying detail is required for this device placement. |
Root Operation Comparison
- Insertion (0THB8MZ) captures the radioactive element placement itself and is always coded when the procedure’s primary intent is to leave the device in the body for localized therapy.
- Excision (0TBB8ZX) is coded separately only when a true diagnostic biopsy is taken, using the diagnostic qualifier “X” rather than “Z.”
- Destruction (0T5B8ZZ) is coded separately when fulguration of tissue is performed in addition to the radioactive substance placement, since it represents a distinct root operation from Insertion.
📝 Coding Examples
Example 1
Clinical Scenario: A patient with a biopsy-confirmed 1.5 cm transitional cell carcinoma at the bladder dome undergoes cystourethroscopy with placement of Iodine-125 radioactive seeds directly into the tumor bed. No additional biopsy or fulguration is performed during this encounter.
| Field | Code | Rationale |
|---|---|---|
| CPT | 52250 | The radioactive substance placement is the sole billable component and fully describes the work performed. |
| PDx | C67.1 | The pathology-confirmed malignant neoplasm of the bladder dome is the primary indication for treatment. |
Note
Confirm the operative note explicitly documents the type and location of the radioactive substance placed, since this is the defining element that distinguishes 52250 from the fulguration- and resection-based codes.
Example 2
Clinical Scenario: During the same cystourethroscopic session, the surgeon obtains a biopsy of a suspicious lesion adjacent to the treated site and fulgurates a small bleeding vessel before placing the radioactive substance.
| Field | Code | Rationale |
|---|---|---|
| CPT 1 | 52250 | Reported once, since the descriptor already includes biopsy and fulguration performed in the same session. |
| CPT 2 | Not separately reported | 52204 and 52224 are bundled into 52250 for the same operative session. |
| PDx | C67.9 | Used because the operative report does not specify the exact bladder subsite for the treated lesion. |
Warning
Do not unbundle the biopsy or fulguration components with modifier -59 unless they were performed at a clearly distinct, separately documented lesion unrelated to the radioactive substance placement site.
Example 3
Clinical Scenario: A patient with a personal history of bladder cancer presents for routine surveillance cystourethroscopy; no recurrence is found and no radioactive substance is placed during this visit.
| Field | Code | Rationale |
|---|---|---|
| CPT | 52000 | A purely diagnostic cystourethroscopy without therapeutic intervention is reported instead of 52250, since no radioactive substance was placed. |
| PDx | Z85.51 | The personal history of malignant neoplasm of the bladder supports the medical necessity of ongoing surveillance. |
Global period reminder, if applicable
⚠️ Common Coding Pitfalls
- Pitfall 1: Reporting 52204 or 52224 in addition to 52250 for biopsy or fulguration performed at the treated lesion during the same session. These components are bundled into 52250 by definition and should not be separately billed absent a distinct, documented second site.
- Pitfall 2: Appending assistant-at-surgery modifiers -80, -81, -82, or -AS without recognizing the statutory payment restriction reflected by the assistant surgeon indicator of 1, which will typically result in denial.
- Pitfall 3: Using a nonspecific diagnosis code such as C67.9 when the pathology report clearly documents a specific bladder subsite, reducing coding specificity and potentially affecting risk adjustment accuracy.
- Pitfall 4: Appending laterality modifiers -RT, -LT, or -50, which do not apply to bladder procedures since the bladder is a single midline organ.
- Pitfall 5: Failing to verify payer-specific medical necessity requirements before scheduling the procedure, since there is no NCD and coverage instead depends on MAC-specific LCDs or commercial UM guidelines requiring a qualifying diagnosis.
- Pitfall 6: Confusing CPT 52250 with older cystotomy-based radioactive material insertion code 51020, which describes an open surgical (not endoscopic) approach and is not interchangeable with 52250.
📎 Sources
1. American Medical Association. CPT 2026 Professional Edition. 2026. 2. AAPC. CPT® Code 52250 — Urethra and Bladder Transurethral Surgical Procedures. 2026. 3. Centers for Medicare & Medicaid Services. Medicare Physician Fee Schedule Relative Value File (PPRRVU), January 2026 Release. 4. Anthem Blue Cross Blue Shield. Clinical UM Guideline CG-SURG-51: Outpatient Cystourethroscopy. Revised May 14, 2026. 5. Centers for Medicare & Medicaid Services. 2026 ICD-10-CM Official Guidelines for Coding and Reporting. 6. Centers for Medicare & Medicaid Services. 2026 ICD-10-PCS Official Guidelines for Coding and Reporting.Sources listed above correspond to superscript citations throughout this note. Verify all Medicare payment figures against your current CMS PFS Lookup tool and applicable MAC LCD prior to claim submission. Please use the latest AAPC/AHIMA Coding Books to verify each code within this note.